Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trialResearch in context

Summary: Background: Microsatellite stable (MSS) and RAS-mutant metastatic colorectal cancer (mCRC) patients are characterized by an immunosuppressive microenvironment and a low response rate to immunotherapy. Chemotherapy and anti-angiogenesis therapy have been reported to potentially promote immu...

Description complète

Détails bibliographiques

Auteurs principaux:	Xuefeng Fang, Ning Zhu, Chenhan Zhong, Liuhong Wang, Jun Li, Shanshan Weng, Hanguang Hu, Caixia Dong, Dan Li, Yongmao Song, Dong Xu, Jianwei Wang, Lifeng Sun, Jian Wang, Zhanhuai Wang, Hongfeng Cao, Xiujun Liao, Ningjuan Yu, Qian Xiao, Mi Mi, Suzhan Zhang, Kefeng Ding, Ying Yuan
Format:	Artigo
Langue:	Inglês
Publié:	Elsevier 2023-08-01
Collection:	EClinicalMedicine
Sujets:	Microsatellite stable RAS mutation Metastatic colorectal cancer Immune checkpoint inhibitors PD-1
Accès en ligne:	http://www.sciencedirect.com/science/article/pii/S2589537023003000
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!